Monitoring of the antiplatelet drugs effect in patients with coronary artery disease: What is the real clinical impact?

Current Vascular Pharmacology

Volumn 5, Issue 4, 2007, Pages 293-301

  Christiaens, Luc ^a   Macchi, Laurent ^b  

^a Département Médico Chirurgical de Cardiologie   (Italy)

^b UNIVERSITÉ DE POITIERS   (France)

Author keywords

Aspirin; Clopidogrel; Coronary artery disease; Platelet aggregation inhibitors; Platelet function

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANALYZER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; FLOW CYTOMETRY; HEART INFARCTION; HUMAN; LABORATORY TEST; LOADING DRUG DOSE; PATIENT COMPLIANCE; REVIEW; RISK REDUCTION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; BLOOD CLOTTING PARAMETERS; DRUG ANTAGONISM; DRUG RESISTANCE; METHODOLOGY;

ASPIRIN; CORONARY ARTERY DISEASE; DRUG MONITORING; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TICLOPIDINE;

EID: 38449111634     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016107782023361     Document Type: Review

References (75)

1. Antiplatelet trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5.
3. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108: 37-42.
4. Christiaens L, Macchi L, Herpin D, Coisne D, Duplantier C, Allal J, et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res 2002; 108: 115-9.
5. Sane DC, Mc Kee SA, Malinin AI, Serebruany VL. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 2002; 90: 983-5.
6. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, et al. Resistance in vitro to low dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T (GP Ia-IIa) and C-5T Kozak (GP Ibα) polymorphisms. J Am Coll Cardiol 2003; 42: 1115-9.
7. Wang JC, Aucoin-Barry D, Manuelian D, Monbouquette R, Reisman M, Gray W, et al. Incidence of aspirin nonresponsiveness using the Ultegra rapid platelet function assay-ASA. Am J Cardiol 2003; 92: 1492-4.
8. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, et al. Functional and biochemical evaluation of aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-7.
9. Coma-Canella I, Velasco A, Castano S. Prevalence of aspirin resistance. Int J Cardiol 2005; 101: 71-6.
10. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003; 89: 783-7.
11. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004; 93: 456-8
12. Grossmann R, Sokolova O, Schnurr A, Bonz A, Porsche C, Obergfell A, et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004; 92: 1201-6.
13. Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004; 110: 1916-9.
14. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392-6.
15. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Barrera-Ramirez C, Sabate M, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005; 115: 101-8.
16. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-51.
17. Michelson AD, Furman MI, Goldschmidt-Clemont P, Mascelli MA, Hendrix C, Coleman L, et al. Platelet GPIIIa P1A1 polymorphisms display different sensitivity to agonists. Circulation 2000; 101: 1013-8.
18. Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572-8.
19. Holmes MB, Kabbani SS, Terrien CM, Watkins MW, Sobel BE, Sneider DJ. Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab. Coron Artery Dis. 2001; 12: 245-53.
20. Madan M, Berkowitz SD, Christie DJ, Smith AC, Sigmon KN, Tcheng JE. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am Heart J 2002; 144: 151-8.
21. Grotemeyer KH, Sharafinski HW, Husstedt IW. Two-year follow-up of aspirin responders and aspirin non-responders. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
22. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-7.
23. Buchanan MR, Schwartz L, Bourassa M, Brister S, Peniston C. BRAT investigators. Results of the BRAT study- a pilot study investigating the possible significance of ASA non responsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000; 16: 1385-90.
24. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
25. Gum P, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-5.
26. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-7.
27. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122-6.
28. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
29. Born G, Horn M. Effects of the numbers and sizes of platelets aggregates on the optical density of plasma. Nature 1967; 215: 1027-9.
30. Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GPIIb/IIIa therapy. Circulation 1997; 96: 3860-6
31. Storey RF, Wilcox RG, Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assays methodology and comparison of different antagonists. Circulation 1998; 98: 1616-21.
32. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152-63.
33. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83: 316-21.
34. Hezard N, Metz D, Nazeyrollas P, Droullé C, Potron G, Nguyen P. PFA-100 and flow cytometry: can they challenge aggregometry to assess anti-platelet agents, other than GPIIbIIIa blockers, in coronary angioplasty? Thromb Res 2002; 108: 43-7.
35. Chakroun T, Gerotziafas G, Robert F, Lecrubier C, Samama MM, Hatmi M, et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124: 80-5
36. Derhaschnig U, Pachinger C, Jilma B. Variable inhibition of highshear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: A randomized, placebo-controlled, clinical trial (abst). Am Heart J 2004; 147: e17.
37. Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, et al. Rapid platelet-function assay. An automated and quantitative cartridge-base method. Circulation 1999; 99: 620-5.
38. A2 polymorphism. Am Heart J 2002; 143: 76-82.
39. Perez de Prado A, Fernandez-Vasquez F, Cuellas JC, Alonso-Orcajo N, Carbonell R, Pascual C, et al. Association between level of platelet inhibition after early use of Abciximab and myocardial reperfusion in ST-elevation acute myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol 2006; 97: 793-803.
40. Wheeler GL, Braden GA, Steinhubl SR, Keriakes DJ, Kottke-Marchand K, Michelson AD, et al. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 2002; 143: 602-11.
41. Malinin AI, Atar D, Callahan KP, McKenzie ME, Serebruany VL. Effect of a single dose aspirin on platelets in human with multiple risk factors for coronary artery disease. Eur J Pharmacol 2003; 462: 139-43.
42. Mirkhel A, Peyster E, Sundeen J, Greene L, Michelson AD, Hasan A, et al. Frequency of aspirin resistance in a community hospital. Am J Cardiol 2006; 98: 577-9.
43. Chen WH, Lee PY, Ng W, Yat-Yin Kwok J, Cheng X, Wai-Luen Lee S, et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol 2005; 96: 760-3.
44. Lee PY, Chen WH, Ng W, Chen X, Yat-Yin Kwok, Tse HF, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005; 118: 723-7.
45. Malinin A, Pokov A, Sperling M, Defranco A, Schwartz K, Schwartz D, et al. Monitoring platelet inhibition after clopidogrel with the Verify Now-P2Y12® rapid analyzer: The Verify Thrombosis risk assessment (VERITAS) study. Thromb Res 2007; 119: 277-84
46. Varon D, Lashevski I, Brenner B, Beyar R, Lanir N, Tamarin I, et al. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998; 135: 187-93.
47. Osende JI, Fuster V, Lev EI, Shimbo D, Ranch U, Marmur JD, et al. Testing platelet activation with a shear-dependent platelet function test vs. aggregation-based tests, relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 2001; 103: 1488-91.
48. Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999; 6: 342-8.
49. Hezard N, Metz D, Nazeyrollas P, Nguyen P, Simon G, Daliphard S, et al. Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA. Thromb Haemost 1999; 81: 869-73.
50. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in humans platelets. Definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82: 1145-52.
51. Geiger J, Teichmann L, Grossman R, Aktas B, Steigerwald U, Walter U, et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005; 51: 957-65.
52. Harrison P, Segal H, Balsbery K, Furtado C, Silber L, Rothwell PM. Screening for aspirin responsiveness after transient ischaemic attack and stroke. Comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005; 36: 1001-5.
53. Macchi L, Sorel N, Christiaens L. Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Design 2006; 12: 251-8.
54. Hovens M, Snoep J, Eikenboom J, van der Bom J, Mertens B, Huisman M. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153: 175-81.
55. Martin CP, Talbert RL. Aspirin resistance: An evaluation of current evidence and measurement methods. Pharmacotherapy 2005; 25: 942-53.
56. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder Status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250: 63-6.
57. Bruno A, McConnell JP, Cohen SN, Tietjen GE, Wallis RA, Gorelick PB, et al. Serial urinary 11-Dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. Stroke 2004; 35: 727-30.
58. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-17.
59. Topol EJ, Gum P, Kottke-Marchant K. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 42: 1336-7.
60. Harrison P, Segal H, Heeling D, Silver L, Coull A, Beavis J, et al. Aspirin resistance detected by high shear platelet function testing within the Oxford Vascular Study (OXVASC) (abst). J Thromb Haemost 2003; suppl 1: P0757.
61. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (Aspirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004; 38: 353-6.
62. CURE Steering Committee. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
63. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
64. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
65. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-6.
66. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovane T, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542-9.
67. Lev El, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary-intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47: 27-33.
68. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, et al. Impact of the degree of per-interventional platelet inhibition after loading dose with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-50.
69. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissher MZ, et al. Clopidogrel effects on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46:1827-32.
70. Ajzenberg N, Aubry P, Huisse MG, Cachier A, El Amara W, Feldman LJ, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol 2005; 45: 1753-6.
71. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, et al. Benefit of a 600mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48: 1339-45.
72. Smith Jr SC, Feldman TE, Hishfeld Jr JW, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary intervention - summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guideline (ACC/AHA/SCAI Writing Committee to update the 2001 guidelines for percutaneous coronary intervention). Circulation 2006; 113: 156-75.
73. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation. 2001; 104: 181-6.
74. Ernst NM, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoomtje JC, et al. Achieved platelet aggregation inhibition after different platelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44: 1187-93.
75. Danzi GB, Capuano C, Sesana M, Mauri L, Sozzi F. Variability in extent of platelet function inhibition after administration of optimal dose of glycoptotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention. Am J Cardiol 2006; 97: 489-93.